Supernus Pharmaceuticals

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. The Company launched Oxtellar XR and Trokendi XR, two novel neurology products for the treatment of epilepsy.  Supernus Pharmaceuticals is also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder and its coexisting disorders, and depression.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2005
Size (employees)
363 (est)+6%
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, US

Key People/Management at Supernus Pharmaceuticals

Jack Khattar

Jack Khattar

President and CEO

Supernus Pharmaceuticals Office Locations

Supernus Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
1550 E Gude Dr

Supernus Pharmaceuticals Financials and Metrics

Supernus Pharmaceuticals Financials

Supernus Pharmaceuticals's revenue was reported to be $57.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

57.6 m

Gross profit (Q1, 2017)

54.6 m

Gross profit margin (Q1, 2017), %

95%

Net income (Q1, 2017)

10.3 m

EBIT (Q1, 2017)

16.8 m

Market capitalization (17-Oct-2017)

2.2 b

Cash (31-Mar-2017)

59.6 m
Supernus Pharmaceuticals's current market capitalization is $2.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

12 m122 m144.4 m215 m

Revenue growth, %

915%18%49%

Cost of goods sold

1.1 m5.8 m8.4 m12 m

Gross profit

10.9 m116.3 m136 m203 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

29.7 m52.5 m28.1 m35.1 m38.6 m43.1 m50.4 m56.8 m57.6 m

Cost of goods sold

1.7 m1.3 m1.6 m1.8 m2.2 m2 m2.8 m3.4 m2.9 m

Gross profit

28 m51.2 m26.5 m33.3 m36.3 m41 m47.7 m53.4 m54.6 m

Gross profit Margin, %

94%97%94%95%94%95%95%94%95%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33 m36.4 m34.2 m66.4 m

Accounts Receivable

5.1 m17.3 m25.9 m41.5 m

Inventories

7.2 m3.8 m5.3 m16.8 m

Current Assets

97.2 m108.9 m106 m151.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

12 m37.8 m25.8 m33.1 m26.3 m19.8 m36.2 m54.3 m59.6 m

Accounts Receivable

10.9 m15.3 m19.3 m17.9 m23.6 m30.7 m34.3 m36.2 m38.9 m

Inventories

10.1 m11.1 m13.7 m13.6 m14.7 m13 m16.4 m17.5 m19.2 m

Current Assets

72 m103 m101.5 m105.7 m102.6 m94 m114.1 m138.2 m149.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.3 m)19.9 m14 m91.2 m

Depreciation and Amortization

742 k928 k921 k2.4 m

Accounts Receivable

(5 m)(12 m)(8.6 m)(15.6 m)

Inventories

(6 m)(6.3 m)854 k(4.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12.3 m)15.5 m917 k2.9 m7.1 m5 m15 m76.9 m10.3 m

Depreciation and Amortization

460 k701 k214 k431 k651 k429 k1.1 m1.7 m741 k

Accounts Receivable

(5.8 m)(10.2 m)(2 m)(630 k)(6.3 m)(4.7 m)(8.4 m)(10.3 m)2.6 m

Inventories

(2.9 m)(4 m)(261 k)(151 k)(1.3 m)(457 k)(3.8 m)(4.9 m)(2.4 m)
USDY, 2017

Revenue/Employee

162.9 k

Financial Leverage

1.6 x
Show all financial metrics

Supernus Pharmaceuticals Market Value History

Traffic Overview of Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Life and Culture

You may also be interested in